QUOTE AND NEWS
newratings.com  Apr 9  Comment 
DUBLIN (dpa-AFX) - Alkermes plc's (ALKS) phase III clinical trial of aripiprazole lauroxil in patients with schizophrenia has demonstrated its ability to provide clinically meaningful symptom control in patients struggling with...
StreetInsider.com  Apr 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Seattle+Genetics+Inc++%28SGEN%29+to+Receive+%246M+ADCETRIS-Related+Milestone/9361610.html for the full story.
Benzinga  Apr 8  Comment 
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result of achieving the first commercial sale of ADCETRIS (brentuximab...
DailyFinance  Apr 7  Comment 
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted research related to its antibody-drug conjugate (ADC) programs and technology in more than 15 presentations at the 105th Annual Meeting of the American Association...
Benzinga  Mar 10  Comment 
In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Buy rating and $65.00 price target. In the report, H.C. Wainwright & Co. noted, “We believe that Adcetris,...
Benzinga  Feb 24  Comment 
In a report published Monday, Bank of America analyst Steve Byrne reinstated coverage on Seattle Genetics (NASDAQ: SGEN) with an Underperform rating and $46.00 price target. In the report, Bank of America noted, “We are reinstating SGEN...
TheStreet.com  Feb 12  Comment 
NEW YORK (TheStreet) -- Seattle Genetics soared to an all-time high of $51.97 on Wednesday morning after the biotech company announced a narrower-than-expected loss in its fourth-quarter results, along with revenues that surpassed analysts'...
StreetInsider.com  Feb 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Needham+%26+Company+Upgrades+Seattle+Genetics+%28SGEN%29+to+Buy%3B+Could+Be+Next+Large+Cap+Drug+Co./9156617.html for the full story.
SeekingAlpha  Feb 12  Comment 
Seattle Genetics Inc. (SGEN) Q4 2013 Results Earnings Conference Call February 11, 2014 4:30 PM ET Executives Peggy Pinkston - Senior Director, Corporate Communications Clay Siegall - President and CEO Todd Simpson - Chief...




 

Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for treating cancer and autoimmune disease.[1] The company is working to develop next generation monoclonal therapies called antibody-drug conjugates (ADCs). The technology links potent synthetic drugs with monoclonal antibodies. The company has collaborations with major industry players all over the world such as: Millennium Pharmaceuticals, Bayer AG (BAYRY), Celldex Therapeutic (BER:TCE1), GlaxoSmithKline (GSK), Genentech (DNA), and quite a few others.[1] Leveraging these collaborations the company is working to navigate the high development costs and regulations that are indicative of the drug industry.

Business Growth

Seattle Genetics does not have any commercial products yet, but had revenue of $107.5 million for 2010. This was an increase of 107% from 2009. The company derived its revenue from payments that included technology access and maintenance fees, milestone and reimbursement payments from its collaborations. Its large jump from 2009 was primarily due to payments received from its collaborations with Genentech, Millennium, and other ADC collaborations.[1]

Trends and Forces

High Costs of Drug Development make it Difficult for Small Companies like Seattle Genetics

For more detailed information on the FDA approval process, see also Clinical trials.

Developing a new drug is a time-consuming and costly endeavor. Hundreds of thousands of candidate compounds must be screened to identify a handful of potential drugs, and even fewer of these candidate drugs are found to be effective at treating a disease. The drug must then pass strict safety standards in several series of clinical trials. The entire process of developing a new drug and bringing it to the market takes up to 10 to 15 years and on average costs $1.3 billion.[2]

Tightening Food and Drug Administration (FDA) Regulations

Beginning in 2009, the FDA implemented a series of reforms that include stricter monitoring of drug adverse events, more funding for the agency, stronger ability to force product recalls, more scientific expertise within the agency, more transparency. Even before 2009 the result has been a much more conservative FDA, demanding more product information.[3]

Competition

The various aspects of patent protection and the extremely high costs of researching and developing drugs marks the pharmaceutical industry with high risk and high competitiveness. It is important to keep in mind when considering a comparison of industry players that competition does not arise between each company as a whole, but rather between specific drug areas and their relative advantages in therapeutic treatment. Due to this fact many of Seattle Genetic's collaborators are competitors since they are developing therapies in similar disease areas. They include:

References

  1. 1.0 1.1 1.2 Seattle Genetics 2010 10k
  2. DiMasi, Joseph, “The Cost of Biopharmaceutical R&D: Is Biotech Different?,” Managerial and Decision Economics, 2007
  3. The FDA: A tough tonic
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki